Biote Enlists Healthcare Veteran to Drive Men’s Hormone Therapy Expansion

With more than 30 years of experience in pharmaceutical sales, business development, strategic marketing, and management, John Denne is expected to spearhead Biote's sales initiatives to fulfill a largely unmet medical need for millions of men seeking safe and effective hormone replacement therapy.

Irving-based Biote Corporation, a preventive healthcare solutions provider that delivers personalized hormone therapy, has appointed John Denne as general manager of its men’s health division. The move is aimed at expanding the company’s presence in the growing market for male hormone replacement therapy.

Biote, which was founded in 2012, went public on Nasdaq in May 2022 through a SPAC deal.

Denne, a healthcare industry veteran with more than 30 years of experience in sales, business development, strategic marketing, and management, is expected to spearhead Biote’s sales initiatives to fulfill a largely unmet medical need for millions of men seeking safe and effective hormone replacement therapy.

A “track record of success”

Denne joins Biote with a track record of success in building brand recognition and helping companies scale business divisions to drive sustainable growth, according to a news release.

Most recently, as the senior director of commercial development at Endo International, a global specialty pharmaceuticals company, he was instrumental in driving the commercial success of new treatments in Men’s Health and Men’s Sexual Health division at the firm, Biote said.

Other roles at healthcare and pharmaceutical companies included stints at Roche Pharmaceuticals, Sunovion Pharmaceuticals, and Biopharm Communication, where Denne honed his expertise in sales, marketing, and management.

Biote’s CEO, Terry Weber says Denne’s impressive track record in building brand recognition and scaling business divisions to achieve sustainable growth was a key factor in his selection for the men’s health division role. “We believe his extensive experience and leadership capabilities will accelerate our expansion into the substantial and underserved market for men’s health,” he said in a statement.

Hormone-related aging conditions—an “underserved” $7 billion global market

“I’m excited to join Biote at this pivotal time of growth and expansion for the company,” Denne said in a statement. “Hormone replacement therapy represents a safe and effective treatment option for millions of men, and I am eager to lead Biote’s strategic efforts to fulfill this largely unmet medical need.”

Biote aims to transform healthy aging through its innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of hormone-related aging conditions—a $7 billion global market the company calls underserved.

According to the news release, Biote wants to drive clinical success for practitioners by offering hormone optimization therapies that are safe and effective and says its personalized approach to hormone therapy has been well-received by practitioners and patients alike, as it provides symptom relief while being affordable and accessible.

Biote’s recent expansion into the hormone replacement therapy market for men through John Denne’s appointment as General Manager of the Men’s Health Division is expected to further strengthen its foothold in the preventive healthcare industry, according to the company.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

  • Today—on the 63rd anniversary of D-Day—the Dallas-based nonprofit changed its name to the Monuments Men and Women Foundation, acknowledging the 27 women members of the allied WWII art rescue team. "This name change has been a long-standing wish of mine," said bestselling Dallas author Robert M. Edsel, the foundation's founder and chairman. "The upcoming opening of the Monuments Men and Women Gallery [at the National World War II Museum] presented just the right opportunity."

  • Irving-based Biote Corp. an innovator in preventive healthcare through the delivery of personalized hormone therapy, announced Debby Morris has been appointed to its board of directors, bringing more than three decades of experience in directing financial operations and strategy to support high-growth companies. Biote went public in May through a SPAC deal. Morris served as the executive vice president and chief financial officer of Apria Inc. from March 2013 through October. Before that, she was chief financial officer-Americas for Sitel Worldwide Corp. from February 2010 to February 2013. “Debby is an accomplished executive whose deep financial and business expertise—spanning accounting…

  • The investment from Cobalt Ventures follows MedArrive's $25 million series A round in November 2021 and brings its total funding to $40.5 million to date. "Everyone in America has a right to inclusive, high-quality care, yet too many are left out and have no one on their side who can connect them to the system," MedArrive Co-Founder and CEO Dan Trigub said. "That's what the MedArrive platform and our field providers offer."

  • Pharos Capital Group Sells Majority Stake in Physical Therapy Group

    Middle Market private equity firm Pharos Capital Group has sold its majority stake in portfolio company MOTION PT Group to Confluent Health. Pharos is headquartered in Dallas and Nashville. No financial details were disclosed. MOTION is a physical therapy, occupational therapy, and speech therapy company with 59 clinic locations across Connecticut, Maryland, Massachusetts, and New York. Jim Phillips, Partner at Pharos, said, "We are pleased that Pharos's support allowed the company to address the pressing need for value-driven, tailored physical therapy services," Pharos Partner Jim Phillips said in a statement. "MOTION's dedication to developing a comprehensive physical therapy service model…

  • Researchers at UT Southwestern Medical Center in Dallas have discovered that could lead to an effective treatment for acute alcohol intoxications. The researchers reported in a new study that a shot of a liver-produced hormone called FGF21 sobered up mice that had passed out from alcohol. It allowed them to regain consciousness and coordination much faster than those that didn’t receive the treatment, UT Southwestern said. Acute alcohol intoxication is responsible for about 1 million emergency room visits in the U.S. each year, UT Southwestern said. “Humans have long searched for agents that could reverse drunkenness, and now we have…